Pulmicort

Proteinuria, Asthma, Itching + 16 more

Treatment

20 Active Studies for Pulmicort

Treatment for

Proteinuria

What is Pulmicort

Budesonide

The Generic name of this drug

Treatment Summary

Budesonide is a corticosteroid used to treat lung and intestinal inflammation caused by asthma, COPD, Crohn's disease, and ulcerative colitis. It was approved by the FDA in 1994 and is available in both oral and inhalation forms.

Rhinocort

is the brand name

Pulmicort Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Rhinocort

Budesonide

1994

134

Effectiveness

How Pulmicort Affects Patients

Budesonide is a drug used to treat breathing and digestive issues by reducing inflammation. The amount of budesonide needed varies from person to person and it is generally considered to be safe. However, it can cause an increase in the hormone cortisol and suppress the adrenal gland. Patients should be warned about these possible side effects.

How Pulmicort works in the body

Corticosteroids reduce swelling, limit nutrient flow to areas of inflammation, and stop white blood cells from traveling there. They act by binding to receptors and changing gene expression, which can prevent cell death, reduce the production of certain acids, and turn off certain inflammatory proteins. Low doses reduce inflammation, while higher doses weaken the immune system. Long-term use of corticosteroids can also raise sodium levels and lower potassium levels.

When to interrupt dosage

The proposed dosage of Pulmicort is contingent upon the ascertained condition, including Vasomotor Rhinitis, Crohn's Disease and Chronic Obstructive Pulmonary Disease (COPD). The dose fluctuates, as per the administration procedure (e.g. Enema; Kit; Tablet - Rectal or Respiratory (inhalation)) highlighted in the table hereunder.

Condition

Dosage

Administration

Asthma

, 0.25 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 0.09 mg, 0.032 mg, 3.0 mg, 0.18 mg, 0.2 mg, 0.5 mg, 9.0 mg, 28.0 mg, 2.3 mg, 0.08 mg, 0.16 mg, 0.00008 mg/hour, 0.32 mg, 1.0 mg, 6.0 mg, 0.125 mg/mL, 4.0 mg, 0.064 mg/pump actuation, 0.4 mg/pump actuation, 0.1 mg/pump actuation, 2.0 mg/pump actuation, 0.2 mg/pump actuation, 0.182 mg/pump actuation

Respiratory (inhalation), Inhalant, , Inhalant - Respiratory (inhalation), Suspension, Suspension - Respiratory (inhalation), Aerosol, powder - Respiratory (inhalation), Aerosol, powder, Spray, metered, Oral, Capsule, Nasal, Spray, metered - Nasal, Capsule - Oral, Powder - Respiratory (inhalation), Aerosol, foam, Aerosol, foam - Rectal, Rectal, Capsule, delayed release pellets, Tablet, extended release - Oral, Tablet, extended release, Enema; Kit; Tablet, Enema; Kit; Tablet - Rectal, Capsule, extended release - Oral, Capsule, extended release, Capsule, coated pellets - Oral, Powder - Nasal; Respiratory (inhalation), Powder, Nasal; Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation), Capsule, gelatin coated, Capsule, gelatin coated - Oral, Inhalant - Oral, Capsule, delayed release pellets - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Powder, metered, Powder, metered - Respiratory (inhalation), Cutaneous, Capsule, delayed release - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Patch - Cutaneous, Patch, Tablet, orally disintegrating - Oral, Kit, Aerosol, metered - Nasal, Capsule, coated pellets, Tablet, orally disintegrating, Kit - Rectal, Capsule, delayed release

Itching

Skin Diseases

Ulcerative Colitis

maintenance therapy

Nasal Polyps

Eosinophilic Esophagitis

Hypersensitivity

Sinusitis

Crohn Disease

Chronic Obstructive Pulmonary Disease

Acute Coryza

Proteinuria

Colitis, Collagenous

Rhinitis, Vasomotor

Crohn's Disease

Nasal Congestion

IGA Glomerulonephritis

Warnings

Pulmicort Contraindications

Condition

Risk Level

Notes

Asthma

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Status Asthmaticus

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Budesonide may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Budesonide may interact with Pulse Frequency

There are 20 known major drug interactions with Pulmicort.

Common Pulmicort Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with Abatacept.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Budesonide.

Abetimus

Major

The risk or severity of adverse effects can be increased when Budesonide is combined with Abetimus.

Pulmicort Toxicity & Overdose Risk

It is uncommon to overdose on corticosteroids, but taking too much over a long period of time can lead to excessive cortisol levels in the body and suppress the adrenal gland. If you suspect an overdose, reduce the dosage temporarily. A 200mg oral dose is fatal to female mice and a 400mg oral dose is fatal to male mice.

Pulmicort Novel Uses: Which Conditions Have a Clinical Trial Featuring Pulmicort?

516 active clinical trials are presently being conducted to assess the effectiveness of Pulmicort in the management of Chronic Obstructive Pulmonary Disease (COPD), Ulcerative Colitis and Allergic conditions.

Condition

Clinical Trials

Trial Phases

Asthma

89 Actively Recruiting

Phase 1, Phase 4, Early Phase 1, Not Applicable, Phase 2, Phase 3

Itching

2 Actively Recruiting

Phase 3, Not Applicable

Chronic Obstructive Pulmonary Disease

71 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Proteinuria

5 Actively Recruiting

Phase 2, Phase 3, Phase 4, Phase 1

IGA Glomerulonephritis

0 Actively Recruiting

Ulcerative Colitis

16 Actively Recruiting

Phase 3, Phase 2, Phase 1, Not Applicable, Phase 4

Sinusitis

0 Actively Recruiting

Crohn's Disease

53 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1

Hypersensitivity

1 Actively Recruiting

Phase 4

Colitis, Collagenous

0 Actively Recruiting

Skin Diseases

0 Actively Recruiting

maintenance therapy

0 Actively Recruiting

Rhinitis, Vasomotor

1 Actively Recruiting

Not Applicable

Eosinophilic Esophagitis

0 Actively Recruiting

Acute Coryza

0 Actively Recruiting

Crohn Disease

0 Actively Recruiting

Nasal Polyps

0 Actively Recruiting

Crohn Disease

0 Actively Recruiting

Nasal Congestion

0 Actively Recruiting

Patient Q&A Section about pulmicort

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Pulmicort nebulizer a steroid?

"Budesonide is used to manage and stop symptoms (wheezing and shortness of breath) that come from asthma. It is a part of a group of drugs termed corticosteroids."

Answered by AI

Does Pulmicort help with coughing?

"Budesonide is a medication used to prevent asthma symptoms such as difficulty breathing, chest tightness, wheezing, and coughing. It is available as a powder for oral inhalation, and can be used by adults and children aged 6 and up."

Answered by AI

What is Pulmicort used to treat?

"PULMICORT FLEXHALER is prescribed to help people with asthma keep their asthma under control. The medicine is for use in adults and children who are at least six years old."

Answered by AI

Is Pulmicort a steroid?

"Pulmicort Flexhaler is a powder that is inhaled to help prevent asthma attacks."

Answered by AI

Clinical Trials for Pulmicort

Have you considered Pulmicort clinical trials?

We made a collection of clinical trials featuring Pulmicort, we think they might fit your search criteria.

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+

All Sexes

Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available

Has No Placebo

Stanford University

Jeff Swigris, DO, MS

Minnesota Health Solutions